KA
EW icon

Kintegral Advisory’s Edwards Lifesciences EW Stock Holding History

Kintegral Advisory’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.09M Sell
63,507
-2,816
-4% -$232K 0.48% 51
2025
Q4 		$5.65M Sell
66,323
-1,815
-3% -$149K 0.48% 52
2025
Q3 		$5.3M Sell
68,138
-305
-0.4% -$23.8K 0.45% 62
2025
Q2 		$5.35M Sell
68,443
-103
-0.2% -$7.68K 0.49% 58
2025
Q1 		$4.97M Sell
68,546
-230
-0.3% -$16.5K 0.5% 58
2024
Q4 		$5.09M Sell
68,776
-3,204
-4% -$224K 0.48% 55
2024
Q3 		$4.75M Sell
71,980
-943
-1% -$68.5K 0.44% 69
2024
Q2 		$6.74M Buy
72,923
+40,223
+123% +$3.56M 0.65% 35
2024
Q1 		$3.12M Sell
32,700
-102
-0.3% -$8.57K 0.31% 90
2023
Q4 		$2.5M Sell
32,802
-208
-0.6% -$14.5K 0.28% 99
2023
Q3 		$2.29M Sell
33,010
-20
-0.1% -$1.61K 0.28% 97
2023
Q2 		$3.12M Hold
33,030
– – 0.37% 83
2023
Q1 		$2.73M Sell
33,030
-1,775
-5% -$140K 0.35% 91
2022
Q4 		$2.6M Buy
34,805
+8,697
+33% +$670K 0.34% 95
2022
Q3 		$2.16M Hold
26,108
– – 0.3% 88
2022
Q2 		$2.48M Buy
26,108
+553
+2% +$57.2K 0.32% 82
2022
Q1 		$3.01M Buy
25,555
+571
+2% +$64.1K 0.33% 79
2021
Q4 		$3.24M Hold
24,984
– – 0.34% 71
2021
Q3 		$2.83M Hold
24,984
– – 0.33% 73
2021
Q2 		$2.59M Hold
24,984
– – 0.31% 82
2021
Q1 		$2.09M Hold
24,984
– – 0.27% 95
2020
Q4 		$2.28M Hold
24,984
– – 0.31% 82
2020
Q3 		$1.99M Sell
24,984
-804
-3% -$62.7K 0.3% 82
2020
Q2 		$1.78M Hold
25,788
– – 0.29% 85
2020
Q1 		$1.62M Buy
25,788
+2,886
+13% +$208K 0.32% 84
2019
Q4 		$1.78M Hold
22,902
– – 0.32% 88
2019
Q3 		$1.68M Hold
22,902
– – 0.33% 87
2019
Q2 		$1.41M Hold
22,902
– – 0.29% 99
2019
Q1 		$1.46M Buy
22,902
+7,251
+46% +$414K 0.31% 93
2018
Q4 		$799K Buy
+15,651
New +$792K 0.24% 99

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Kintegral Advisory's EW Position: Q1 2026 in Review

Kintegral Advisory reduced its Edwards Lifesciences (EW) stake by 4.2% in Q1 2026, selling an estimated $232K and leaving 63,507 shares worth $5.09M. The position accounts for 0.48% of the portfolio, ranked #51.

Kintegral Advisory first reported a position in EW in Q4 2018 and has held it in 30 quarters since. The position peaked at $6.74M in Q2 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Kintegral Advisory held 63,507 shares of Edwards Lifesciences worth $5.09M as of Q1 2026.
  • Kintegral Advisory sold 2,816 Edwards Lifesciences shares in Q1 2026, an estimated $232K.
  • Edwards Lifesciences made up 0.48% of Kintegral Advisory's portfolio in Q1 2026, its #51 holding.
  • Kintegral Advisory first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 30 quarters since.
  • Kintegral Advisory's Edwards Lifesciences position peaked at $6.74M in Q2 2024.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Kintegral Advisory's 13F filing for Q1 2026, filed 14 May 2026.